Stock Information

• Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26
  Fri, Apr 3, 2026 6:02 PM
• Alnylam Pharmaceuticals shares are trading lower after reports suggesting that the Trump administration is preparing to invoke Section 232 tariffs on pharmaceutical producers that don't already have a pricing agreement with the U.S. government.
  Thu, Apr 2, 2026 2:18 PM
• 5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
  Wed, Apr 1, 2026 11:05 AM
• Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Combines Strong Growth with a Technical Breakout Setup
  Wed, Apr 1, 2026 8:41 AM
• First Bancorp And 2 Other Stocks That May Be Trading Below Their Estimated Worth
  Tue, Mar 31, 2026 5:38 PM
• Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now
  Tue, Mar 31, 2026 3:06 PM
• Three Stocks That Could Be Trading Below Estimated Value In March 2026
  Tue, Mar 31, 2026 11:38 AM
• 3 Prominent Stocks Estimated To Be Trading At Discounts Up To 45.1%
  Mon, Mar 30, 2026 5:38 PM
• New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
  Mon, Mar 30, 2026 5:00 PM
• Alnylam Presents New Clinical, Real-World Data From Cardiovascular Portfolio At ACC.26, Reinforcing Potential Of RNAi To Deliver Fundamentally Differentiated, Effective, And Durable Impact For Patients Living With CVD
  Mon, Mar 30, 2026 1:03 PM

Financial data not available